Return to the Home Page

Go to this topic's parent

Go to the previous topic in the book structure

Go to the next topic in the book structure

Search the site

Octreotide

(Octreotide (Hospira), Sandostatin™)

Class: growth hormone inhibitor

Indication: acromegaly, gastro-entero pancreatic endocrine tumours, post pancreatic surgery, emergency treatment to stop bleeding oesophageal varices

Unlicensed indications: antisecretory in intestinal obstruction, secretory diarrhoea, high fistula output, variceal bleeds

Contraindications/cautions: diabetes

Adverse reactions:

Metabolism/clearance: metabolised by the liver

Interactions:

Dosing:

Syringe driver: see syringe driver compatibility table.

Mechanism of Action: blocks somatostatin receptors

Peak effect: 30 minutes

Duration: 12 hours

Availability:

Full funding on Special Authority.

Cost: Approx $5.13 to $35.00 per normal release inj, $1,772 to $2,951 per LAR inj

Notes:

Return to the Home Page

Topic Code: 19446